Pulmonary hypertension profiles of the patients at diagnosis
| BB | No BB | Partial BB | p-value | |
| Subjects n | 133 | 375 | 60 | |
| RA dilatation | 75 (97) | 250 (97) | 60 (100) | 0.82 |
| RV dilatation | 61 (79) | 206 (80) | 46 (77) | 0.90 |
| TR jet velocity cm·s-1 | 407±71 | 405±73 | 435±61 | 0.74 |
| Positive bubble study | 8 (10) | 27 (11) | 4 (7) | 0.97 |
| RVSP mmHg | 73±23 | 74±24 | 77±27 | 0.68 |
| sPAP mmHg | 74±19 | 75±21 | 81±23 | 0.41 |
| dPAP mmHg | 30±9 | 32±11 | 35±12 | 0.08 |
| mPAP mmHg | 45±11 | 47±14 | 51±16 | 0.08 |
| PCWP mmHg | 9±3 | 10±6 | 10±3 | 0.16 |
| Pulmonary vascular resistance Wood units | 9±5 | 10±6 | 11±7 | 0.16 |
| Cardiac index (Fick) L·min-1·m-2 | 2.6±0.9 | 2.4±2 | 2.5±1.8 | 0.04 |
| Cardiac output (Fick) L·min-1 | 4.9±2 | 4.5±2 | 4.5±2 | 0.04 |
| Pulmonary arterial oxygen saturation % | 63±12 | 64±13 | 62±11 | 0.41 |
| PAH medications | ||||
| Epoprostenol | 33 (25) | 127 (34) | 21 (35) | 0.05 |
| Sildenafil | 66 (50) | 144 (38) | 28 (46) | 0.02 |
| Bosentan | 32 (24) | 112 (30) | 20 (33) | 0.20 |
| Treprostinil | 11 (8) | 41 (11) | 8 (13) | 0.37 |
| Ambrisentan | 15 (11) | 18 (5) | 9 (15) | 0.10 |
| Tadalafil | 12 (9) | 19 (5) | 6 (10) | 0.10 |
| Iloprost | 4 (3) | 11 (3) | 3 (5) | 0.96 |
| Oxygen therapy | 29 (22) | 84 (23) | 17 (28) | 0.86 |
Data are presented as n (%) or mean±sd, unless otherwise stated. n=568. BB: patients who had continued to use β-blockers until they reached the end-points of the study; no BB: patients who had never used β-blockers; partial BB: patients who were started on β-blocker therapy but discontinued after a period; RA: right atrium; RV: right ventricle; TR: tricuspid regurgitation; RVSP: right ventricular systolic pressure; sPAP: systolic pulmonary artery pressure; dPAP: diastolic pulmonary artery pressure; mPAP: mean pulmonary artery pressure; PCWP: pulmonary capillary wedge pressure; PAH: pulmonary arterial hypertension.